Journal of Clinical Pediatrics >
Detection of urine glycosaminoglycans by liquid chromatography-tandem mass spectrometry in the diagnosis and follow-up of patients with mucopolysaccharidosis
Received date: 2024-01-23
Online published: 2024-05-10
Objective To establish a method to determine chondroitin sulfate (CS), dermatan sulfate (DS) and heparan sulfate (HS) in urine by liquid chromatography tandem mass spectrometry (LC-MS/MS), and to investigate the application of urine glycosaminoglycans detection in the diagnosis and follow-up of mucopolysaccharidosis (MPS) patients. Methods Twenty urine samples from MPS patients and 37 urine samples from normal children were collected, and glycosaminoglycans levels in these samples were determined. Urine samples were added and dried under nitrogen. Then the samples were derivatized with methanol hydrochloride and dried under nitrogen. After reconstituted, the glycosaminoglycans were analyzed by LC-MS/MS. The linearity, limit of quantification, precision, spiked recoveries, and matrix effect were evaluated. Results The linearity of CS, DS and HS by LC-MS/MS was>0.99. The limits of quantification for CS, DS and HS were 0.5 mg/L, 1 mg/L and 1 mg/L, respectively; the intra-day imprecision ranged from 1.9% to 10.4%, and the inter-day imprecision ranged from 2.6% to 9.8%; and the recovery ranged from 85.6% to 110.4%, the relative matrix effect ranged from 84.9% to 115.5%. CS, DS and HS in urine samples of normal children were normally distributed, then the upper limit of reference interval were preliminarily determined by mean+1.64 SD, which were 16.5 mg/mmol, 1.8 mg/mmol and 1.4 mg/mmol, respectively. Urine GAGs of MPS patients were analyzed, the LC-MS/MS method was effective in detecting MPSⅠ, MPSⅡ, MPSⅢ and MPSⅥ patients. Urine samples of MPSⅠ or MPSⅡ patients who had hematopoietic stem cell transplantation showed reduced DS and HS concentration. Conclusion LC-MS/MS has good performance in detecting urinary mucopolysaccharides and is expected to be used for accurate diagnosis and treatment follow-up monitoring of MPS patients.
Xia ZHAN , Xiaolan GAO , Wenjun JI , Siyu CHANG , Dan LIU , Huiwen Zhang . Detection of urine glycosaminoglycans by liquid chromatography-tandem mass spectrometry in the diagnosis and follow-up of patients with mucopolysaccharidosis[J]. Journal of Clinical Pediatrics, 2024 , 42(5) : 399 -406 . DOI: 10.12372/jcp.2024.24e0050
[1] | Peterson S, Liu J. Deciphering mode of action of heparanase using structurally defined oligosaccharides[J]. J Biol Chem, 2012, 287(41): 34836-34843. |
[2] | Kakkis E, Marsden D. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses[J]. Mol Genet Metab, 2020, 130(1):7-15. |
[3] | Bobillo Lobato J, Jiménez Hidalgo M, Jiménez Jiménez LM. Biomarkers in lysosomal storage diseases[J]. Diseases, 2016, 4(4):40-57. |
[4] | 张惠文, 王瑜, 叶军, 等. 黏多糖贮积症47例的常见酶学分型[J]. 中华儿科杂志, 2009, 47(4): 276-280. |
[5] | Gray G, Claridge P, Jenkinson L, et al. Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses: an evaluation[J]. Ann Clin Biochem, 2007, 44: 360-363. |
[6] | 雷红林, 叶军, 张惠文, 等. 35例黏多糖贮积症Ⅳ型患儿临床特点及酶学诊断[J]. 临床儿科杂志, 2012, 30(5): 442-445. |
[7] | de Jong JG, Wevers RA, Laarakkers C, et al. Dimethylmethylene blue-basedspectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses[J]. Clin Chem, 1989, 35 (7): 1472-1477. |
[8] | 中华医学会检验医学分会,卫生计生委临床检验中心. 液相色谱-质谱临床应用建议[J]. 中华检验医学杂志, 2017, 40(10): 770-779. |
[9] | 中国医师协会检验医师分会临床质谱检验医学专业委员会. 液相色谱串联质谱临床检测方法的开发与验证[J]. 检验医学, 2019, 34(3): 189-196. |
[10] | 常思宇, 高晓岚, 王瑜, 等. 溶酶体贮积症1 520例疾病谱分析[J]. 中华实用儿科临床杂志, 2023, 38(1) : 60-63. |
[11] | Lin HY, Tu RY, Chern SR, et al. Identification and functional characterization of IDS gene mutations underlying taiwanese hunter syndrome (Mucopolysaccharidosis Type II)[J]. Int J Mol Sci, 2019, 21(1):114-131. |
[12] | Lamanna WC, Lawrence R, Sarrazin S, et al. Secondary storage of dermatan sulfate in Sanfilippo disease[J]. J Biol Chem, 2011, 286(9): 6955-6962. |
[13] | 中华医学会儿科学分会内分泌遗传代谢学组. 黏多糖贮积症Ⅱ型临床诊断与治疗专家共识[J]. 中华儿科杂志, 2021, 59(6): 446-451. |
[14] | 中华医学会儿科学分会血液学组. 异基因造血干细胞移植治疗黏多糖贮积症儿科专家共识[J]. 中国小儿血液与肿瘤杂志, 2017, 22(5): 227-230. |
[15] | 中华医学会儿科学分会内分泌遗传代谢学组. 黏多糖贮积症Ⅰ型诊疗专家共识(2022)[J]. 中华儿科杂志, 2023, 61(3) : 203-208. |
[16] | Bigger BW, Begley DJ, Virgintino D, et al. Anatomical changes and pathophysiology of the brain in mucopoly-saccharidosis disorders[J]. Mol Genet Metab, 2018, 125(4): 322-331. |
[17] | Guffon N, Bertrand Y, Forest I, et al. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years[J]. J Pediatr, 2009, 154(5): 733-737. |
[18] | Tanaka A, Okuyama T, Suzuki Y, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan[J]. Mol Genet Metab, 2012, 107(3): 513-520. |
[19] | Li R, Tian L, Gao Q, et al. Establishment of cutoff values for newborn screening of six lysosomal storage disorders by tandem mass spectrometry[J]. Front Pediatr, 2022, 10: 814461. |
[20] | Chen T, Fan C, Huang Y, et al. Genomic sequencing as a first-tier screening test and outcomes of newborn screening[J]. JAMA Network Open, 2023, 6(9): e2331162. |
[21] | Kubaski F, Mason RW, Nakatomi A, et al. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry[J]. J Inherit Metab Dis, 2017, 40(1): 151-158. |
/
〈 |
|
〉 |